Literature DB >> 16508338

Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice.

Viktor Johanson1, Yvonne Arvidsson, Lars Kölby, Peter Bernhardt, Christina Swärd, Ola Nilsson, Håkan Ahlman.   

Abstract

CHS 828, a cyanoguanidine with potent experimental antitumoural activity, inhibits activation of nuclear factor-kappaB. In the present study, marked antitumoural activity of peroral CHS 828 was shown against three different human neuroendocrine tumours, midgut carcinoid (GOT1), pancreatic carcinoid (BON), and medullary thyroid carcinoma (GOT2), transplanted in nude mice. Our results indicate that CHS 828 can be a candidate drug for treatment of neuroendocrine tumours.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16508338     DOI： 10.1159/000091754

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN： 0028-3835            Impact factor:   4.914


  5 in total

Review 1.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

2.  Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments.

Authors:  Dieter Fuchs; Rolf Christofferson; Mats Stridsberg; Elin Lindhagen; Faranak Azarbayjani
Journal:  J Transl Med       Date:  2009-03-12       Impact factor: 5.531

3.  Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.

Authors:  Nadia Sawicka-Gutaj; Joanna Waligórska-Stachura; Mirosław Andrusiewicz; Maciej Biczysko; Jerzy Sowiński; Jerzy Skrobisz; Marek Ruchała
Journal:  Tumour Biol       Date:  2015-05-07

4.  Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.

Authors:  Anne-Julie Cloux; Dominique Aubry; Mathieu Heulot; Christian Widmann; Oussama ElMokh; Francesco Piacente; Michele Cea; Alessio Nencioni; Axel Bellotti; Karima Bouzourène; Maxime Pellegrin; Lucia Mazzolai; Michel A Duchosal; Aimable Nahimana
Journal:  Oncotarget       Date:  2019-11-19

5.  Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.

Authors:  Oussama ElMokh; Saki Matsumoto; Aimable Nahimana; Michel A Duchosal; Paulina Biniecka; Axel Bellotti; Karin Schaeuble; Francesco Piacente; Hector Gallart-Ayala; Julijana Ivanisevic; Ivan Stamenkovic; Alessio Nencioni
Journal:  Cell Death Dis       Date:  2022-04-08       Impact factor: 8.469
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.